Novabridge Biosciences (NBP)
NASDAQ:NBP
Want to see NBP full AI Analyst Report?
NBP Stock Chart & Stats
$2.70
--
Market closed
$2.70
--
Day’s Range― - ―
52-Week Range$0.90 - $6.79
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.03M
Market Cap
$197.30M
Enterprise Value$173.19M
Total Cash (Recent Filing)$30.14M
Total Debt (Recent Filing)$438.46K
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding115,381,690
10 Day Avg. Volume1,007,174
30 Day Avg. Volume1,026,881
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-8.04
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.49
Forecast
1Y Price Target
$9.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Solid Cash RunwayManagement disclosed a $210.8M year-end 2025 cash balance expected to fund operations through 2028. This multi-year runway provides durable financing optionality, reduces immediate dilution pressure and allows focus on advancing pivotal trials and regulatory milestones without urgent capital raises.
Regulatory Progress For GivastomigFDA feedback indicating potential accelerated approval eligibility for givastomig, based on strong Phase 1b data, materially de-risks the development path. A defined regulatory route and the ability to base registrational trials on objective response endpoints shorten time-to-market and enhance long-term commercial prospects.
Low LeverageThe balance sheet shows very low debt levels (around 1% D/E in 2025), which reduces solvency risk and preserves financial flexibility. Low leverage supports the company’s capacity to fund R&D or strategic transactions and withstand development volatility without excessive interest or covenant constraints.
Bears Say
Sustained Cash BurnOperating and free cash flows have been negative every year from 2021–2025, reflecting persistent cash burn. Ongoing negative cash generation steadily depletes reserves, creates recurring financing needs, raises dilution risk, and limits the firm's ability to scale programs without external capital or partnerships.
Recurring Losses & Minimal RevenueSince 2021 the company has posted heavy recurring losses and revenue fell to near-zero in 2024–2025. Persistent unprofitability and an unstable revenue base undermine self-funding, depress returns on equity, and make long-term survival and growth contingent on successful asset commercialization or deal revenue.
Platform Dependent On Clinical Outcomes & PartnersNovaBridge’s hub-and-spoke model focuses on de-risking assets to proof-of-concept and relying on partnerships or exits for commercialization. This structural reliance makes growth contingent on binary trial outcomes and third-party deals, increasing execution risk and timing uncertainty for sustainable revenue generation.
NovaBridge Biosciences News
NBP FAQ
What was Novabridge Biosciences’s price range in the past 12 months?
Novabridge Biosciences lowest stock price was $0.90 and its highest was $6.79 in the past 12 months.
What is Novabridge Biosciences’s market cap?
Novabridge Biosciences’s market cap is $197.30M.
When is Novabridge Biosciences’s upcoming earnings report date?
Novabridge Biosciences’s upcoming earnings report date is Sep 01, 2026 which is in 103 days.
How were Novabridge Biosciences’s earnings last quarter?
Currently, no data Available
Is Novabridge Biosciences overvalued?
According to Wall Street analysts Novabridge Biosciences’s price is currently Undervalued.
Does Novabridge Biosciences pay dividends?
Novabridge Biosciences does not currently pay dividends.
What is Novabridge Biosciences’s EPS estimate?
Novabridge Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novabridge Biosciences have?
Novabridge Biosciences has 115,381,690 shares outstanding.
What happened to Novabridge Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Novabridge Biosciences?
Currently, no hedge funds are holding shares in NBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovaBridge Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (233.33% Upside)
$9.00 (233.33% Upside)
Blogger Sentiment
Bullish
NBP Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $534.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Company Description
Novabridge Biosciences
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
NBP Stock 12 Month Forecast
Average Price Target
$9.00
▲(233.33% Upside)
Ownership Overview
0.20% Insiders
0.07% Mutual Funds
13.39% Other Institutional Investors
85.40% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---